A randomized double-blind investigation of cefroxadine (CGP 9000) versus cephalexin in urinary tract infection.
A total of 64 out-patients with significant urinary tract infection were randomly allocated to treatment with cefroxadine 250 mg q.i.d. or cephalexin 500 mg q.i.d. for ten days. Urine cultures were performed before allocation to the treatment groups and on Days 0, 1, 3, 7 and 21. Twenty patients discontinued treatment prematurely because of insignificant bacteriuria on Day 0. Both drug regimes--the cefroxadine dose was half that of cephalexin--showed good activity during treatment, and no statistically significant differences were found between the two drugs. At follow-up, several relapses were found in both treatment groups. Adverse drug reactions were only reported by three patients in the cefroxadine group, and by none in the cephalexin group.
D000328:Adult; D000368:Aged; D001437:Bacteriuria / Q000188:drug therapy; D002506:Cephalexin / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D002515:Cephradine / Q000031:analogs & derivatives / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D013293:Enterococcus faecalis; D004927:Escherichia coli Infections / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D013290:Streptococcal Infections / Q000188:drug therapy*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D002511:Cephalosporins; C012671:cefroxadine; D002515:Cephradine; D002506:Cephalexin